Literature DB >> 27431344

Use of Biologics in Sjögren's Syndrome.

Gaetane Nocturne1, Divi Cornec2, Raphaèle Seror1, Xavier Mariette3.   

Abstract

The management of patients suffering from primary Sjögren syndrome (pSS) has long been mainly symptomatic and demonstration of effectiveness of systemic drugs was lacking. However, progress made in the understanding of pSS pathogenesis has allowed moving into a more targeted approach to therapeutic intervention. Given the key role of chronic B-cell activation, B-cell target therapies were the first candidates. New pathways are currently being investigated, including costimulation and ectopic germinal center. In this review, we summarize the current evidence regarding B-cell targeted and anti-TNF therapies and provide an overview of promising drugs in the pipeline.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biological treatment; B cell; Clinical trials; Outcome measure; Primary Sjögren’s syndrome

Mesh：

Substances：

Year:  2016        PMID： 27431344     DOI： 10.1016/j.rdc.2016.03.001

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN： 0889-857X            Impact factor:   2.670


  8 in total

Review 1.  Advances in the diagnosis and treatment of Sjogren's syndrome.

Authors:  Xiaoyun Chen; Huaxun Wu; Wei Wei
Journal:  Clin Rheumatol       Date:  2018-05-26       Impact factor: 2.980

2.  Oral dryness and Sjögren's: an update.

Authors:  P J Shirlaw; A Khan
Journal:  Br Dent J       Date:  2017-11-10       Impact factor: 1.626

3.  BAFF-driven B cell hyperplasia underlies lung disease in common variable immunodeficiency.

Authors:  Paul J Maglione; Gavin Gyimesi; Montserrat Cols; Lin Radigan; Huaibin M Ko; Tamar Weinberger; Brian H Lee; Emilie K Grasset; Adeeb H Rahman; Andrea Cerutti; Charlotte Cunningham-Rundles
Journal:  JCI Insight       Date:  2019-03-07

Review 4.  Innate immunity in Sjögren's syndrome.

Authors:  Jeremy Kiripolsky; Liam G McCabe; Jill M Kramer
Journal:  Clin Immunol       Date:  2017-04-08       Impact factor: 3.969

Review 5.  Research status and future prospects of extracellular vesicles in primary Sjögren's syndrome.

Authors:  Jingwen Zhao; Qi An; Xueqing Zhu; Baoqi Yang; Xinnan Gao; Yuhu Niu; Liyun Zhang; Ke Xu; Dan Ma
Journal:  Stem Cell Res Ther       Date:  2022-06-03       Impact factor: 8.079

6.  Sjögren's syndrome: state of the art on clinical practice guidelines.

Authors:  Vasco C Romão; Rosaria Talarico; Carlo Alberto Scirè; Ana Vieira; Tobias Alexander; Chiara Baldini; Jacques-Eric Gottenberg; Heidi Gruner; Eric Hachulla; Luc Mouthon; Martina Orlandi; Cristina Pamfil; Marc Pineton de Chambrun; Marco Taglietti; Natasa Toplak; Paul van Daele; Jacob M van Laar; Stefano Bombardieri; Matthias Schneider; Vanessa Smith; Maurizio Cutolo; Marta Mosca; Xavier Mariette
Journal:  RMD Open       Date:  2018-10-18

7.  Discrepancy of Serological and Molecular Patterns of Circulating Epstein-Barr Virus Reactivation in Primary Sjögren's Syndrome.

Authors:  Armen Sanosyan; Claire Daien; Anaïz Nutz; Karine Bollore; Anne-Sophie Bedin; Jacques Morel; Valérie Zimmermann; Gaetane Nocturne; Marianne Peries; Nicolas Guigue; Jacques-Eric Gottenberg; Philippe Van de Perre; Xavier Mariette; Edouard Tuaillon
Journal:  Front Immunol       Date:  2019-05-29       Impact factor: 7.561

8.  Overlapping Sjogren's syndrome reduces the probability of reaching target in rheumatoid arthritis patients: a propensity score matched real-world cohort from 2009 to 2019.

Authors:  Huijuan Zhang; Haoze Zhang; Dai Gao; Wenhui Xie; Yan Geng; Zhuoli Zhang
Journal:  Arthritis Res Ther       Date:  2020-05-01       Impact factor: 5.156
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.